Adial Pharmaceuticals, Inc.
ADIL Nasdaq
SEC CIK 1513525
Follow Adial Pharmaceuticals
Weekly email: filings, results, news
Net income
−$52M
−2555.2% vs same quarter last year
EPS, diluted
−$11.25
−144% vs same quarter last year
Operating cash flow
−$6.4M
−263.7% vs same quarter last year
Operating income
−$52M
−2664.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$7.98T |
| FY24 | −$13.2T |
| FY23 | −$5.12T |
| FY22 | −$12.7M |
| FY21 | −$19.4M |
| FY20 | −$10.9M |
| FY19 | −$8.6M |
| FY18 | −$11.6M |
| FY17 | −$1.1M |
| FY16 | - |
News
No stories filed under Adial Pharmaceuticals yet - coverage appears here as the news feed clusters it.